Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

- PMLiVE

Distribution of Novartis’ generic Zantac halted due to carcinogen concerns

Ranitidine medicines found to contain cancer-causing substance

- PMLiVE

Novartis eyes potential new indication for Cosentyx

Unveils positive late-stage results in axial spondyloarthritis

Biomarin

NICE approves BioMarin’s Brineura after initial setback

First treatment for rare disease

- PMLiVE

Novartis’ CAR-T Kymriah scores SMC approval

Will now be available on NHS across the UK

- PMLiVE

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

Provides hope for new treatment of rare cancer

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

Novartis building

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

- PMLiVE

Novartis scores promising phase 3 MS study

Takes fight to Roche’s blockbuster ocrevus

- PMLiVE

NICE’s long-serving chief exec Sir Andrew Dillon to step down

Pharma leader praises "laser focus" on thorny access questions

- PMLiVE

NICE’s fast-track catapults Skyrizi into market

Watchdog also gives direction on comparing rival treatments

- PMLiVE

Novartis chooses internal replacement for US pharma president role

Victor Bulto to lead US pharma business

Novartis day

Senators attack Novartis over ‘unconscionable’ handling of Zolgensma data

Ask FDA to hold the company ‘accountable’

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links